Clinical Trials Logo

Stage IV Breast Cancer clinical trials

View clinical trials related to Stage IV Breast Cancer.

Filter by:

NCT ID: NCT00998738 Terminated - Pain Clinical Trials

Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

Start date: November 2009
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies calcium and magnesium to see how well they work in preventing peripheral neuropathy caused by ixabepilone in patients with breast cancer. Giving calcium together with magnesium may stop or delay the development of peripheral neuropathy in patients with cancer who are receiving treatment with ixabepilone. It is not yet known whether calcium and magnesium are effective in preventing peripheral neuropathy caused by ixabepilone.

NCT ID: NCT00937482 Terminated - Clinical trials for Stage IV Breast Cancer

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Start date: August 2009
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of cediranib maleate when given together with whole brain radiation therapy in treating patients with brain metastases from non-small cell lung cancer. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays and other types of radiation to kill cancer cells and shrink tumors. Giving cediranib maleate together with radiation therapy may kill more tumor cells

NCT ID: NCT00132002 Terminated - Clinical trials for Stage IV Breast Cancer

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT00095888 Terminated - Clinical trials for Stage IV Breast Cancer

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining 3-AP with gemcitabine in treating patients who have refractory metastatic breast cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining 3-AP with gemcitabine may kill more tumor cells

NCT ID: NCT00079326 Terminated - Clinical trials for HER2-positive Breast Cancer

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

Start date: January 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving trastuzumab together with ixabepilone works in treating women with HER2-positive metastatic breast cancer. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with ixabepilone may kill more tumor cells.

NCT ID: NCT00071942 Terminated - Clinical trials for Stage IV Breast Cancer

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Start date: October 2003
Phase: Phase 1
Study type: Interventional

Vaccines may make the body build an immune response to kill tumor cells. This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with metastatic breast cancer.

NCT ID: NCT00063934 Terminated - Clinical trials for Stage IV Breast Cancer

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Start date: May 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of oblimersen when given together with doxorubicin and docetaxel and to see how well they work in treating women with metastatic or locally advanced breast cancer. Drugs used in chemotherapy, such as doxorubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin and docetaxel by making the tumor cells more sensitive to the drugs.

NCT ID: NCT00039455 Terminated - Clinical trials for HER2-positive Breast Cancer

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Start date: April 2002
Phase: Phase 1
Study type: Interventional

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with flavopiridol may kill more tumor cells. Phase I trial to study the effectiveness of combining trastuzumab with flavopiridol in treating patients who have metastatic breast cancer

NCT ID: NCT00016276 Terminated - Clinical trials for Stage IV Breast Cancer

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

Start date: May 2001
Phase: Phase 3
Study type: Interventional

Randomized phase III trial to compare the effectiveness of combination chemotherapy, surgery, and radiation therapy with or without dexrazoxane and trastuzumab in treating women who have stage IIIA, stage IIIB or stage IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if chemotherapy combined with surgery and radiation therapy is more effective with or without dexrazoxane and trastuzumab in treating breast cancer

NCT ID: NCT00003454 Terminated - Clinical trials for Stage IV Breast Cancer

Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer

Start date: March 18, 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial studies the effectiveness of antineoplaston therapy in treating women who have stage IV breast cancer that has not responded to previous therapy.